Press Release Distribution

Members Login  |  Register  |  Why Join?   Follow us on Google+Follow us on TwitterFind us on LinkedInFind Us on FacebookSubscribe to our RSS FeedsSubscribe to our YouTube ChannelFind us on RebelMouse

Video Releases    |    Pricing & Distribution Plans    |    Today's News    |    News By Category    |    News By Date    |    Business Directory
All Press Releases for October 12, 2012 »
RSS Feeds RSS Feed     Print this news Printer Friendly     Email this news Email It    Create PDF PDF Version   

Jasper Williams of Sioux Falls, SD: New Drug May Improve Fragile X Syndrome in Children with Autism

A new study indicates that a drug to treat Fragile X syndrome may be on the horizon. Jasper Williams of Sioux Falls, SD supports the efforts to improve the lives of those with autism.
x-small text small text medium text large text

    PHILADELPHIA, PA, October 12, 2012 /24-7PressRelease/ -- Autism is a condition that, only relatively recently, has been truly analyzed and investigated by the medical community. Today, healthcare professionals know more about the autism spectrum disorders than ever before--and they are putting their knowledge to use in developing medications to combat the symptoms of the condition. According to Time, an experimental drug has proven promising as a potential treatment for Fragile X syndrome, which affects many individuals who have autism. Jasper Williams of Sioux Falls, SD is excited by this news, as his two children have autism and he is a strong advocate for any initiative that seeks to improve the lives of those living with the condition.

According to the article, the drug in question is called arbaclofen, or STX209. This particular formula was derived from that of baclofen, which is an FDA-approved pharmaceutical that is prescribed to treat muscle spasticity. Eric Hollander, of the Montefiore/Albert Einstein School of Medicine in New York, has noted that this is a study to keep an eye on, as it is "of interest to the entire field of neurodevelopmental disorders."

STX209 addresses the missing FMR1 gene and has been found to be successful in mice. Dr. Elizabeth Berry-Kravis from the Rush University Medical Center, who is the lead author on the trial, explains: "It's not a cure-all. But this is [the] first example of a moderately large clinical trial that took a drug that was developed on the basis of research in mice and fly models of Fragile X, and theoretically corrects the deficit at a neuronal level."

"This is a promising study," states Jasper Williams of Sioux Falls, SD. "As a father of two sons who have autism, the prospect of a medication that might be able to improve their social skills and reduce the sensory overload that they experience gives me great hope. The fear that our boys will not be able to function independently as adults is very real; however, if this medication can reduce their social deficits and dampen sensory overstimulation, they may very well be able to assimilate into society."

Williams looks forward to seeing how the medication will continue to develop, and he hopes that, ultimately, it will be available to the mass market to assist individuals who have autism in better functioning in social environments.


Jasper Williams of Sioux Falls, SD is the father of two children, both of who have autism. A strong advocate for autism awareness organizations and efforts to improve the symptoms of the condition, he works to increase the understanding of autism throughout his community. Jasper Williams of Sioux Falls, SD is also an avid home chef who enjoys preparing meals for his family and exploring the culinary traditions of the south. Additionally, Jasper Williams of Sioux Falls, SD supports the National Park Service and the work that it does in protecting and preserving the natural, cultural, and historical treasures of the nation.


Press release service and press release distribution provided by

# # #

Contact Information:
Samuel Bennett
PR Management

Philadelphia, PA
Voice: 484-362-9658
E-Mail: Email us Here
Website: Visit Our Website
If you have any questions regarding information in this press release, please contact the person listed in the contact module of this page. Please do not attempt to contact 24-7PressRelease. We are unable to assist you with any information regarding this release. 24-7PressRelease disclaims any content contained in this press release. Please see our complete Terms of Service disclaimer for more information.